Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

HISTORICAL FACTS: Fulcrum therapeutics s return on capital employed overview - Caught on Camera

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q4 sales of $5.06 million. Earnings fell to a loss of $23.48 million, resulting in a 13.36% decrease from last quarter. Fulcrum Therapeutics collected $4.93 million in revenue during Q3, but reported earnings showed a $20.72 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.